血液分析仪市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

血液分析仪市场按产品(仪器(3 部分血液分析仪、5 部分血液分析仪、即时检测血液分析仪等)、试剂和服务)、最终用户(医院、临床实验室、研究机构)细分和其他)和地理(北美、欧洲、亚太地区、中东和非洲以及南美)。该报告提供了上述细分市场的价值(以百万美元计)。

市场快照

Hematology Analyzers Market 1
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

血液分析仪市场预计在预测期内的复合年增长率为 7.6%。

全世界越来越关注用于评估 COVID-19 的血液学参数。研究机构进行了几项研究,许多医院开始使用血液分析仪来测试和监测 COVID-19 患者,而不会传播病毒。为了对大量人群进行实用有效的 COVID-19 感染筛查,中国的一些研究建议在实验室检查中包括白细胞 (WBC) 和 C 反应蛋白 (CRP),以早期监测感染。2020 年 3 月 18 日,Sight 宣布以色列政府运营的 Sheba Tel Hashomer 医院正在使用其 OLO,这是第一个用于即时护理的血液计数设备,用于进行 CBC 测试以监测和治疗其 COVID-19 患者以降低风险的污染。

此外,发表在 Physiological Review-Journal 上的评论表明,参与血栓预防的高水平酶可能是发生 COVID-19 的常见风险因素。此外,鉴于大流行的迅速传播和迄今为止有限的文献,对受血液疾病影响的患者的冠状病毒 (COVID-19) 感染进行正确治疗和管理可能具有挑战性。

此外,血液分析仪市场增长的主要因素包括血液疾病负担的增加、技术进步的增加以及自动化血液学仪器的采用率不断提高。

血液疾病已成为具有不同原因的全球健康问题,并与高死亡率有关。血液疾病,例如贫血、血癌、出血性疾病和血液感染,每年影响各年龄段的数百万人。根据澳大利亚联邦 2018 年的数据,每年有超过 330,000 名受影响的婴儿出生(83% 的镰状细胞疾病和 17% 的地中海贫血),约 7% 的孕妇是血红蛋白疾病的携带者,超过 1% 的夫妇处于危险之中在全球范围内。根据世界血友病联合会的数据,2019 年,全球男性血友病患病率约为 17/10 万男性。此外,血友病确诊人数从 1999 年的 78,629 人增加到 2018 年的 210,454 人。

同样,根据 2019 年全球血友病护理报告,全球有超过 1,125,000 名男性患有遗传性出血性疾病,其中 418,000 人患有最严重的未确诊疾病。早期诊断和治疗是保护血细胞疾病患者生活质量的最佳方法。因此,血液疾病负担的增加可能会在未来推动市场。

然而,血液分析仪的高成本以及与之相关的耗时且严格的监管政策正在抑制整体市场的增长。

报告范围

根据本报告的范围,血液分析仪是用于对血液样本进行测试的设备,它们在医学领域用于确定白细胞计数、全血计数、网织红细胞分析和凝血测试。血液分析仪市场按产品(仪器(3 部分血液分析仪、5 部分血液分析仪、即时检测血液分析仪等)、试剂和服务)、最终用户(医院、临床实验室和研究机构和其他最终用户)和地理(北美、欧洲、亚太地区、中东和非洲以及南美)。该报告提供了上述细分市场的价值(以百万美元计)。

By Product Type
Instruments
3 Part Hematology Analyzer
5 Part Hematology Analyzer
Point-of-care Testing Hematology Analyzers
Others
Reagents
Services
By End User
Hospitals
Clinical Laboratories
Research Institutes
Other End Users
By Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

3 部分血液分析仪是预计将占据最大市场份额的仪器细分市场

随着 COVID-19 病例的增加,以及对跨国运输的封锁和抑制,被发现对系统的供应链产生了影响。最初,由于发现影响细分市场增长的劳动力不足,许多制造商因此停止了生产。然而,对用于评估 COVID-19 的血液学参数的日益关注增加了对血液分析仪的需求。在 COVID-19 大流行的情况下,3 部分血液分析仪被发现具有成本效益,因为测试所需的样本量很大。此外,在 COVID-19 大流行之后,需求也可能激增。

此外,三部分差分细胞计数器使用库尔特原理来确定细胞的大小和体积。样品被裂解并溶解在一个容器中的电解质溶液中,该容器还装有一个较小的容器。3 部分血液分析仪系统非常适合执行中等复杂测试的医师办公室实验室、诊所和小型医院。对 5 部分血液分析仪的兴趣越来越大,但是,3 部分血液分析仪对于常规血液学测试更具成本效益。此外,随着技术的进步和这些工具在全球范围内的可用性以及可负担性,预计市场将出现显着增长。

2019 年 3 月,Transasia Bio-Medicals Ltd 在印度推出了由 Transasia 的全资欧洲子公司 Erba Lachema 制造的 3-Part Differential (3PD) 全自动血液分析仪、试剂和对照品。2019 年 9 月晚些时候,Transasia Bio-Medicals Ltd. 宣布已在印度成功售出 1,000 多台 Erba Hematology 系列分析仪。

2019 年 4 月,Prestige Diagnostics 在全球推出了新的 Hematron 3 PLUS 血液分析仪。它是一款 3 部分差分血液分析仪,能够执行 18 个参数和 3 个直方图。

此外,作为最终用户的临床实验室是进行血液学测试的中心。通常,他们拥有高质量的设备,并且从中获得的结果是准确的。实验室的自动化增加了该领域的设备成本,然而,这些实验室的分析仪并不经常更换。临床检测实验室对全血、血清、尿液、脑脊液和其他体液进行各种检测。此外,便利和准确的结果是推动该细分市场在预测期内增长的两个主要原因。

Hematology Analyzer

北美有望主导研究市场

The rising COVID-19 cases and the lockdown and inhibitions on the intercountry transport were found to have an impact on the supply chain of the systems. Initially, many manufacturers have thus stopped production due to the lack of labor that is found impacting the segment growth. However, the increasing focus on hematology parameters for the assessment of COVID-19 has increased the demand for hematology analyzers. In the case of the COVID-19 pandemic, 3-part hematology analyzers were found to be cost-effective as the samples required to test are huge. Furthermore, demand may surge post the COVID-19 pandemic also.

Moreover, A 3-part differential cell counter uses Coulter's Principle to find the size and volume of the cell. The sample is lysed and dissolved into an electrolyte solution in a container, which holds a smaller container. 3-part hematology analyzer systems are ideally suited for physician office laboratories, clinics, and small hospitals that perform moderately complex testing. There is increased interest in 5-part hematology analyzers. However, 3-part hematology analyzers are more cost-effective for routine hematological tests. Furthermore, with advancements in technology and availability of these instruments across the world coupled with affordability, the market is projected to have notable growth.

In March 2019, Transasia Bio-Medicals Ltd launched the 3-Part Differential (3PD) fully automated hematology analyzers, reagents, and controls in India manufactured by Erba Lachema, a fully owned European subsidiary of Transasia. Later in September 2019, Transasia Bio-Medicals Ltd. announced that it has successfully sold over 1,000 units of its Erba Hematology range of analyzers in India.

In April 2019, Prestige Diagnostics launched its NEW Hematron 3 PLUS Hematology Analyzer, globally. It is a 3-part differential hematology analyzer capable of performing 18 parameters with 3 histograms.

Furthermore, the clinical laboratories as end users are the centers where hematology tests are performed. Usually, they have high-quality equipment, and the results obtained from them are accurate. The automation of laboratories has increased the equipment costs in this segment. However, analyzers are not frequently replaced in these laboratories. The clinical testing laboratories perform various tests on whole blood, serum, urine, cerebrospinal fluids, and other body fluids. Furthermore, convenience and accurate results are the two major reasons driving the growth of the segment over the forecast period.

The United States is one of the most COVID-affected countries across the world. Due to the outbreak of COVID-19, the market is expected to face a slight setback owing to the delay in diagnosis, drug shortages, and others. However The outbreak of COVID-19 is expected to impact the market, as individuals with blood conditions, such as hemophilia, should take extra precautions to minimize the risk of contracting COVID-19, as this group of the population is more prone to infectious diseases.

The market for hematology analyzers in the North American region is growing at a steady pace. This can be attributed to the increasing burden of blood disorders and the growth in the adoption of hematology analyzers by the diagnostic industry. For instance, anemia, which is a common disorder, affects more than three million Americans, particularly women of ‘childbearing age.

According to the World Federation of Hemophilia 2018 report, in 2018, there were about 17,757 people diagnosed with hemophilia in the United States. Furthermore, in 2019, the number of people with hemophilia in the United States increased to about 20,000 individuals, as per NHF (National Health Federation). According to the Leukemia and Lymphoma Society, every three minutes, a person in the United States is diagnosed with blood cancer. About 176,200 people in the United States were diagnosed with leukemia, lymphoma, or myeloma, in 2019.

Many market players are present in the country and are continuously focusing on the development and introduction of novel products. In December 2019, Beckman Coulter subsidiary of Danaher Corporation had launched a new DxH 690T hematology analyzer, designed to help laboratories streamline workflow and maximize uptime. Similarly, in April 2019, Ortho Clinical Diagnostics, in collaboration with Diazyme Laboratories Inc., launched its D-Dimer assay, the latest offering in Ortho’s MicroTip Partnership Assay (MPA) program for coagulation testing in the United States.

Moreover, In the United States, there are a number of associations helping both clinicians and scientists across the world who are working to conquer such blood diseases. Furthermore, many centers in the state are international leaders in the diagnosis and treatment of blood diseases and collaborate in many research projects to improve diagnosis and treatment options for blood diseases. These factors drive the demand for hematology analyzers in the North American region.

Hematology Analyzers Market - Growth Rate by Region

竞争格局

由于存在各种市场参与者,所研究的市场是一个分散的市场。部分市场参与者包括 Abbott Laboratories、Beckman Coulter Inc.(Danaher Corporation)、Bio-Rad Laboratories、Boule Diagnostics AB、F Hoffmann-La Roche Ltd、Hobira Ltd、Nihon Kohden Corporation、Mindray Medical International Limited(Shenzhen Mindray Bio- Medical Electronics Co. Ltd)、Siemens Healthineers 和 Sysmex Corporation。

竞争格局

由于存在各种市场参与者,所研究的市场是一个分散的市场。部分市场参与者包括 Abbott Laboratories、Beckman Coulter Inc.(Danaher Corporation)、Bio-Rad Laboratories、Boule Diagnostics AB、F Hoffmann-La Roche Ltd、Hobira Ltd、Nihon Kohden Corporation、Mindray Medical International Limited(Shenzhen Mindray Bio- Medical Electronics Co. Ltd)、Siemens Healthineers 和 Sysmex Corporation。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Burden of Blood Disorders

      2. 4.2.2 Increasing Technological Advancements

      3. 4.2.3 Rising Adoption Rates of Automated Hematology Instruments

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Hematology Analyzers

      2. 4.3.2 Time-consuming and Stringent Rregulatory Policies

    4. 4.4 Industry Attractiveness - Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Buyers/Consumers

      2. 4.4.2 Bargaining Power of Suppliers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Instruments

        1. 5.1.1.1 3 Part Hematology Analyzer

        2. 5.1.1.2 5 Part Hematology Analyzer

        3. 5.1.1.3 Point-of-care Testing Hematology Analyzers

        4. 5.1.1.4 Others

      2. 5.1.2 Reagents

      3. 5.1.3 Services

    2. 5.2 By End User

      1. 5.2.1 Hospitals

      2. 5.2.2 Clinical Laboratories

      3. 5.2.3 Research Institutes

      4. 5.2.4 Other End Users

    3. 5.3 By Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Beckman Coulter Inc. (Danaher Corporation)

      3. 6.1.3 Bio-Rad Laboratories

      4. 6.1.4 Boule Diagnostics AB

      5. 6.1.5 F Hoffmann-La Roche Ltd

      6. 6.1.6 Horiba Ltd

      7. 6.1.7 Nihon Kohden Corporation

      8. 6.1.8 Mindray Medical International Limited (Shenzhen Mindray Bio-Medical Electronics Co, Ltd)

      9. 6.1.9 Siemens Healthineers

      10. 6.1.10 Sysmex Corporation

      11. 6.1.11 Stratec Biomedical Systems (DIATRON)

      12. 6.1.12 ORTHO CLINICAL DIAGNOSTICS

      13. 6.1.13 ACCUREX BIOMEDICAL PVT. LTD

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Hematology Analyzers Market market is studied from 2018 - 2026.

The Global Hematology Analyzers Market is growing at a CAGR of 7.6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Abbott Laboratories, HORIBA Ltd, Siemens Healthineers, Sysmex Corporation, Danaher Corporation are the major companies operating in Global Hematology Analyzers Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!